Bionime Corporation (4737.TW)
TWD 54.4
(0.18%)
TWD 54.4
(0.18%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.42 Billion TWD | 17.98% |
| 2022 | 2.05 Billion TWD | 15.59% |
| 2021 | 1.77 Billion TWD | 6.9% |
| 2020 | 1.66 Billion TWD | 11.99% |
| 2019 | 1.48 Billion TWD | -11.85% |
| 2018 | 1.68 Billion TWD | 0.01% |
| 2017 | 1.68 Billion TWD | 72.84% |
| 2016 | 974.81 Million TWD | 10.49% |
| 2015 | 882.26 Million TWD | -56.29% |
| 2014 | 2.01 Billion TWD | -19.99% |
| 2013 | 2.52 Billion TWD | 11.87% |
| 2012 | 2.25 Billion TWD | 100.35% |
| 2011 | 1.12 Billion TWD | 395.17% |
| 2010 | -381.3 Million TWD | -55.16% |
| 2009 | -245.74 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 2.56 Billion TWD | 5.02% |
| 2024 Q1 | 2.44 Billion TWD | 0.62% |
| 2023 Q3 | 2.34 Billion TWD | 9.0% |
| 2023 FY | 2.42 Billion TWD | 17.98% |
| 2023 Q1 | 2.02 Billion TWD | -1.35% |
| 2023 Q2 | 2.15 Billion TWD | 6.04% |
| 2023 Q4 | 2.42 Billion TWD | 3.46% |
| 2022 Q3 | 2.04 Billion TWD | 7.49% |
| 2022 FY | 2.05 Billion TWD | 15.59% |
| 2022 Q4 | 2.05 Billion TWD | 0.31% |
| 2022 Q2 | 1.9 Billion TWD | -0.74% |
| 2022 Q1 | 1.92 Billion TWD | 8.01% |
| 2021 Q1 | 1.61 Billion TWD | -3.2% |
| 2021 FY | 1.77 Billion TWD | 6.9% |
| 2021 Q3 | 1.76 Billion TWD | 5.92% |
| 2021 Q4 | 1.77 Billion TWD | 0.74% |
| 2021 Q2 | 1.66 Billion TWD | 3.5% |
| 2020 Q1 | 1.42 Billion TWD | -3.84% |
| 2020 Q4 | 1.66 Billion TWD | 1.1% |
| 2020 FY | 1.66 Billion TWD | 11.99% |
| 2020 Q2 | 1.51 Billion TWD | 5.78% |
| 2020 Q3 | 1.64 Billion TWD | 8.91% |
| 2019 Q2 | 1.43 Billion TWD | -12.98% |
| 2019 Q4 | 1.48 Billion TWD | -5.29% |
| 2019 FY | 1.48 Billion TWD | -11.85% |
| 2019 Q1 | 1.65 Billion TWD | -1.89% |
| 2019 Q3 | 1.56 Billion TWD | 9.02% |
| 2018 Q4 | 1.68 Billion TWD | 6.06% |
| 2018 FY | 1.68 Billion TWD | 0.01% |
| 2018 Q3 | 1.58 Billion TWD | 25.6% |
| 2018 Q2 | 1.26 Billion TWD | -18.32% |
| 2018 Q1 | 1.54 Billion TWD | -8.08% |
| 2017 Q3 | 1.74 Billion TWD | 27.07% |
| 2017 Q2 | 1.36 Billion TWD | 26.5% |
| 2017 Q1 | 1.08 Billion TWD | 11.09% |
| 2017 FY | 1.68 Billion TWD | 72.84% |
| 2017 Q4 | 1.68 Billion TWD | -3.21% |
| 2016 Q3 | 1.05 Billion TWD | -5.94% |
| 2016 Q4 | 974.81 Million TWD | -7.32% |
| 2016 FY | 974.81 Million TWD | 10.49% |
| 2016 Q1 | 1.25 Billion TWD | 42.7% |
| 2016 Q2 | 1.11 Billion TWD | -11.18% |
| 2015 Q1 | 2.01 Billion TWD | -0.19% |
| 2015 Q2 | 2.03 Billion TWD | 0.83% |
| 2015 Q3 | 2.08 Billion TWD | 2.64% |
| 2015 FY | 882.26 Million TWD | -56.29% |
| 2015 Q4 | 882.26 Million TWD | -57.68% |
| 2014 Q3 | 2.44 Billion TWD | 0.02% |
| 2014 Q1 | 2.48 Billion TWD | -1.61% |
| 2014 FY | 2.01 Billion TWD | -19.99% |
| 2014 Q4 | 2.01 Billion TWD | -17.3% |
| 2014 Q2 | 2.44 Billion TWD | -1.68% |
| 2013 FY | 2.52 Billion TWD | 11.87% |
| 2013 Q3 | 2.44 Billion TWD | 6.59% |
| 2013 Q4 | 2.52 Billion TWD | 3.32% |
| 2013 Q1 | 2.32 Billion TWD | 3.19% |
| 2013 Q2 | 2.29 Billion TWD | -1.56% |
| 2012 Q1 | 1.16 Billion TWD | 3.78% |
| 2012 FY | 2.25 Billion TWD | 100.35% |
| 2012 Q4 | 2.25 Billion TWD | 18.22% |
| 2012 Q3 | 1.9 Billion TWD | 37.36% |
| 2012 Q2 | 1.38 Billion TWD | 18.88% |
| 2011 Q1 | -369.22 Million TWD | 3.17% |
| 2011 Q4 | 1.12 Billion TWD | -5.8% |
| 2011 FY | 1.12 Billion TWD | 395.17% |
| 2011 Q3 | 1.19 Billion TWD | 457.04% |
| 2011 Q2 | -334.63 Million TWD | 9.37% |
| 2010 FY | -381.3 Million TWD | -55.16% |
| 2010 Q4 | -381.3 Million TWD | 0.0% |
| 2009 FY | -245.74 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 227.48 Million TWD | -966.16% |
| Maxigen Biotech Inc. | -431.03 Million TWD | 662.69% |
| SciVision Biotech Inc. | -163.18 Million TWD | 1586.246% |
| Pegavision Corporation | 63.52 Million TWD | -3718.105% |
| Visco Vision Inc. | 563 Million TWD | -330.789% |